Related Experiment Video
Updated: Jul 11, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Virotherapy as Gene Deliver for Anti-Cancer Therapy: A Review Article
Fakhren Nukha Zalfa1, Nurul Hikma Suciani1, Putu Ananda Arviana Dewi1
1Department of Applied Science, Faculty of Mathematics and Natural Science, Universitas Negeri Malang, Malang City, Indonesia.
Abstract:
This review identifies Adenovirus (AdV) as a leading candidate for gene therapy due to its high transduction efficiency and large gene-carrying capacity, supported by evidence of its progression to phase III clinical trials. However, the interpretation of findings is limited by variations in study designs, potential publication bias, and possible exclusion of relevant studies. As the field continues to evolve with new vector technologies, future research should focus on improving vector safety, specificity, and long-term outcomes to maximize the therapeutic potential of virotherapy.
Objective:
Cancer is the second leading cause of death worldwide. Treatments like chemotherapy and radiotherapy are commonly used, but they have side effects and complications. Gene therapy, using viral vectors like retroviruses, Adenovirus (AdV), and Adeno-Associated Virus (AAV), offers a new approach to overcome these limitations by specifically targeting cancer cells' genetics. This article was developed as a review to compare the effectiveness of different viruses in virotherapy for cancer treatment.
Methods:
This article employed a narrative literature review and qualitative content analysis to synthesize current knowledge on the topic. More than 85 peer-reviewed articles published between 2016 and 2024 were collected from databases such as ScienceDirect, PubMed, Scopus, and Nature. The search used relevant keywords with Boolean operators (AND, OR) to refine results. Articles were selected based on language (English), publication type (peer-reviewed), and relevance to the topic. The selected literature was analyzed to identify recurring patterns, key themes, and significant insights.
Result:
The research results indicate that viruses demonstrated vary levels of efficacy. Retroviruses have a 40%-60% transduction efficiency, can integrate into the host genome, and infect only dividing cells. Adenovirus (AdV) has a 98% efficiency in hepatocellular carcinoma and 70%-80% in other cancers, delivers genetic material without integration, infects both dividing and non-dividing cells, and has a gene capacity of 37 kb. Adeno-Associated Virus (AAV) has a 30%-50% efficiency, a gene capacity of 4.8 kb, and also shows therapeutic potential.
Conclusion:
Each virotherapy agent used in gene therapy exhibits varying efficacy against cancer cells, indicating specific mechanisms unique to each virotherapy agent.
Insights
Adenovirus (AdV) shows high efficiency for gene therapy, making it a promising candidate for cancer treatment. Further research is needed to optimize vector safety and specificity for improved therapeutic outcomes in virotherapy.
Area of Science:
- Oncology
- Gene Therapy
- Virology
Background:
- Cancer remains a leading global cause of death, with conventional treatments like chemotherapy and radiotherapy causing significant side effects.
- Gene therapy offers a novel approach to cancer treatment by targeting cancer cells' genetics, potentially overcoming limitations of traditional methods.
- Viral vectors, including retroviruses, Adenovirus (AdV), and Adeno-Associated Virus (AAV), are key tools in gene therapy and virotherapy.
Purpose of the Study:
- This review compares the efficacy of different viral vectors in virotherapy for cancer treatment.
- To synthesize current knowledge on viral vector effectiveness in targeting cancer cells.
- To evaluate Adenovirus (AdV) as a leading candidate for gene therapy applications.
Main Methods:
- A narrative literature review and qualitative content analysis were performed.
- Over 85 peer-reviewed articles published between 2016 and 2024 were systematically collected and analyzed.
- Databases searched included ScienceDirect, PubMed, Scopus, and Nature, using relevant keywords and Boolean operators.
Main Results:
- Adenovirus (AdV) exhibits high transduction efficiency (up to 98% in hepatocellular carcinoma) and a large gene capacity (37 kb), infecting both dividing and non-dividing cells.
- Retroviruses show 40%-60% transduction efficiency and integrate into the host genome, targeting only dividing cells.
- Adeno-Associated Virus (AAV) has a 30%-50% efficiency and a smaller gene capacity (4.8 kb), also demonstrating therapeutic potential.
Conclusions:
- Different virotherapy agents possess unique mechanisms and varying efficacy against cancer cells.
- Adenovirus (AdV) is identified as a strong candidate for gene therapy due to its efficiency and capacity.
- Optimizing vector safety, specificity, and long-term outcomes is crucial for maximizing the therapeutic potential of virotherapy.
More Related Videos
Related Concept Videos
Gene Therapy
Cancer
Gene Therapy
Mechanisms of Retrovirus-induced Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mechanisms of Retrovirus-induced Cancers

